주메뉴 바로가기 본문 바로가기

아산 주요뉴스 모아보기

  • 2025년도 서울아산병원 임상약리학과 임상강사 모집 - 모집인원: 3명
    - 지원자격: 임상약리 전공의 과정 수료자, 타과 전문의 자격 소지자
    - 모집기간: 상시 모집 (~2025.08)
    자세히보기

닫기

논문/저서

논문/저서 상세페이지
Induction of immunoglobulin transcription factor 2 and resistance to MEK inhibitor in melanoma cells.

Oncotarget. 2017 Jun 20;8(25):41387-41400. doi: 10.18632/oncotarget.17866.

Induction of immunoglobulin transcription factor 2 and resistance to MEK inhibitor in melanomacells.

Hur EH, Goo BKMoon JChoi YHwang JJKim CSBae KSChoi JCho SYYang SHSeo JLee GLee JH.

 

Abstract

Primary or acquired resistance to MEK inhibitors has been a barrier to successful treatment with MEK inhibitors in many tumors. In this study, we analyzed genome-wide gene expression profiling data from 6 sensitive and 6 resistant cell lines to identify candidate genes whose expression changes are associated with responses to a MEK inhibitor, selumetinib (AZD6244). Of 62 identified differentially expressed genes, we selected Immunoglobulin Transcription Factor 2, also known as transcription factor 4 as a potential drug resistance marker for further analysis. This was because the ITF-2 expression increase in resistant cell lines was relatively high and a previous study has suggested that ITF-2 functions as an oncogene in human colon cancers. We also established an AZD6244 resistant cell line (M14/AZD-3) from an AZD6244 sensitive M14 cell line. The expression of the ITF-2 was elevated both in primary AZD6244 resistant cell line, LOX-IMVI and acquired resistant cell line, M14/AZD-3. Targeted silencing of ITF-2 by siRNA significantly enhanced susceptibility to AZD6244 in resistant cells. Wnt/β-catenin pathway was activated through direct interaction of p-ERK and GSK3β. Our results suggest that up-regulation of the ITF-2 gene expression is associated with cellular resistance to MEK inhibitors, and activation of Wnt signaling pathway through interaction of p-ERK and GSK3β seems to be a mechanism for increase of ITF-2.

 

KEYWORDS:

ITF-2; MAPK; beta-catenin; melanomaresistance

 

PMID:

28574827

PMCID:

PMC5522248

DOI:

10.18632/oncotarget.17866

 

 

  • 현재 페이지를 인쇄하기
페이지 처음으로 이동
05505 서울특별시 송파구 올림픽로 43길 88 서울아산병원
TEL 1688-7575 webmaster@amc.seoul.kr
Copyright@2014 by Asan Medical Center. All Rights reserved.
  • 바로가기
  • 바로가기
  • 바로가기
  • 바로가기
  • 서울아산병원, 19년 연속 존경받는 병원 1위
  • 서울아산병원, 美 뉴스위크 평가 세계 22위·국내 1위
  • 서울아산병원, 정보보호 관리체계 ISMS 인증 획득